Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel added to capecitabine and oxaliplatin for first-line metastatic oesophagogastric cancer
NL-OMON44538Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel, capecitabine and oxaliplatin in gastric cancer (GC), esophageal cancer and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Nov 2014; status: active, not recruiting.
02
Drugs
nab-paclitaxelcapecitabineoxaliplatin
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON44538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44538.